2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2457

Ankylosing Spondylitis and a Diagnostic Dilemma: Coccydynia
Abstract Number: 529

Ankylosing Spondylitis and Dysfunctional Dkk
Abstract Number: 2777

Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: Part of a Common Spectrum Or Distinct Diseases? Analysis of a Longitudinal Prospective Cohort
Abstract Number: 2494

Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopaptidase 1 Variants In Antigen Presentaing Cells Affect HLA-B27 Free Heavy Chain Expression and Binding To NK-Cell Receptors
Abstract Number: 538

Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase 1 Variants Alter The Unfolded Protein Response
Abstract Number: 2776

Ankylosing Spondylitis Is Associated With An Increased Likelihood Of Cardiovascular Disease: A Nationwide Matched Cohort Study In Primary Care
Abstract Number: 2495

Ankylosing Spondylitis Protective Endoplasmic Reticulum Aminopeptidase 1 Variants Lead To Decreased Natural Killer Cell Conjugation and Activation
Abstract Number: 547

Anti Ribosomal P Antibodies Accelerate Lupus Glomerulonephritis and Induce Lupus Nephritis In Naive Mice
Abstract Number: 1

Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity
Abstract Number: 1304

Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Abstract Number: 910

Anti-Carbamylated Protein Antibodies (Anti-CarP) Precede The Onset Of Rheumatoid Arthritis
Abstract Number: 869

Anti-Carbamylated Protein Antibodies Are Present Prior To The Diagnosis Of Rheumatoid Arthritis and Predict Future Disease Onset
Abstract Number: 2302

Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis
Abstract Number: 2412

Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis
Abstract Number: 2293

Anti-Citrullinated Peptide/Protein Antibody Specificities and Subclinical Synovitis In Palindromic Rheumatism: Towards a Better Understanding Of The Relationship With Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].